Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Neoplasm
83%
Non Small Cell Lung Cancer
66%
Solid Malignant Neoplasm
58%
Epidermal Growth Factor Receptor
35%
Chemotherapy
34%
Immunoglobulin E
33%
Diseases
31%
Pharmacokinetic
29%
Lung Cancer
27%
Immunotherapy
26%
Mesothelioma
21%
Immunoglobulin E Antibody
21%
Melanoma
19%
Antibody Drug Conjugate
19%
Antitumor Activity
18%
Adverse Event
18%
Protein Tyrosine Kinase Inhibitor
17%
Clinical Trial
17%
Combination Therapy
15%
Head and Neck Squamous Cell Carcinoma
15%
Folate Receptor 1
15%
Maximum Tolerated Dose
15%
Afatinib
14%
Programmed Death 1 Ligand 1
14%
Overall Survival
14%
Ovary Cancer
13%
Tolerability
12%
Progression Free Survival
12%
Dyspnea
12%
Pemetrexed
12%
Monoclonal Antibody
11%
Pharmacodynamics
11%
Phase I Trials
11%
Cisplatin
11%
Technetium 99m
11%
Cetuximab
11%
Proteochondroitin Sulfate
11%
Pembrolizumab
9%
Paclitaxel
9%
Pleura Mesothelioma
8%
Docetaxel
8%
Advanced Cancer
8%
Trastuzumab
8%
Carboplatin
8%
Receptor
8%
Breast Cancer
7%
Nanobody
7%
Reoviridae
7%
Epertinib
7%
Medicine and Dentistry
Neoplasm
62%
Malignant Neoplasm
57%
Non Small Cell Lung Cancer
48%
Pleura Mesothelioma
42%
Mesothelioma
38%
Melanoma
32%
Lung Cancer
30%
Immunotherapy
29%
Epidermal Growth Factor Receptor
25%
Diseases
23%
COVID-19
23%
Ovarian Cancer
19%
Overall Survival
19%
Pleurectomy
18%
Decortication
17%
Progression Free Survival
15%
Radiation Therapy
15%
Programmed Death 1 Ligand 1
14%
Monoclonal Antibody
13%
Pneumonectomy
13%
Folate Receptor 1
13%
Macrophage
13%
Pembrolizumab
13%
T Cell
12%
Technetium-99
12%
Positron Emission Tomography-Computed Tomography
12%
Antibody-Drug Conjugate
11%
Combination Therapy
11%
Cancer Therapy
11%
Proteochondroitin Sulfate
11%
ErbB
11%
Pegargiminase
11%
Argininosuccinate Synthase
11%
Immune Response
10%
Immunoglobulin E
10%
Cisplatin
10%
Lavage
10%
Povidone Iodine
9%
Cytotoxic T-Cell
9%
Cancer Treatment
9%
Adverse Event
9%
Receptor
9%
Dyspnea
8%
Clinical Trial
8%
Pemetrexed
8%
Biological Marker
8%
Single-Photon Emission Computed Tomography
8%
Adjuvant Chemotherapy
8%
Nanobody
8%
Immunoglobulin E Antibody
7%
Immunology and Microbiology
Immunoglobulin E
80%
Immunoglobulin E Antibody
54%
Immunotherapy
37%
Macrophage
26%
B Cell
24%
Antibody Drug Conjugate
23%
Chondroitin Sulfate Proteoglycan
23%
Effector Cell
22%
Tumor Cell
22%
Tumor Antigen
21%
Immune Response
20%
T Cell
20%
Monoclonal Antibody
20%
Immunosurveillance
16%
Cancer Cell
15%
Xenograft
12%
Therapeutic Antibodies
11%
Antineoplastic Activity
10%
Cytotoxic T-Cell
10%
Fc Receptor
10%
Programmed Death 1 Ligand 1
9%
Trastuzumab
9%
Basophil
9%
Mediator
9%
Immunoglobulin G1
9%
Melanoma Antigen
8%
Hypersensitive Response
8%
Immunocompetent Cell
8%
Chimeric Antigen Receptor T-Cell
7%
Tumor-Associated Macrophage
7%
Process Development
7%
Immunoglobulin G4
7%
Neck
7%
Molecular Imaging
7%
Positron Emission Tomography-Computed Tomography
7%
Regulatory T Cell
7%
T Cell Receptor
7%
Antibody-Dependent Cell-Mediated Cytotoxicity
6%
Progression Free Survival
6%
Cancer Immunotherapy
6%
Antigen Specificity
6%
Overall Survival
6%
Tumor Necrosis Factor
6%
Reoviridae
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Immune System
6%
Natural Killer Cell
5%
Isotype
5%
Programmed Death-Ligand 1
5%
Squamous Cell
5%
